BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Maloney SM, Hoover CA, Morejon-Lasso LV, Prosperi JR. Mechanisms of Taxane Resistance. Cancers (Basel). 2020;12. [PMID: 33182737 DOI: 10.3390/cancers12113323] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
Number Citing Articles
1 Barbolina MV. Dichotomous role of microtubule associated protein tau as a biomarker of response to and a target for increasing efficacy of taxane treatment in cancers of epithelial origin. Pharmacol Res 2021;168:105585. [PMID: 33798735 DOI: 10.1016/j.phrs.2021.105585] [Reference Citation Analysis]
2 Manivannan S, Nagaraj S, Narayan S. A Reflection on the Mechanism of the Role of Nanoparticles in Increasing the Efficacy of Anti-tumour Properties of Docetaxel. Curr Pathobiol Rep 2021;9:79-91. [DOI: 10.1007/s40139-021-00223-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
3 Doldi V, El Bezawy R, Zaffaroni N. MicroRNAs as Epigenetic Determinants of Treatment Response and Potential Therapeutic Targets in Prostate Cancer. Cancers (Basel) 2021;13:2380. [PMID: 34069147 DOI: 10.3390/cancers13102380] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Juanes MA. Cytoskeletal Control and Wnt Signaling-APC's Dual Contributions in Stem Cell Division and Colorectal Cancer. Cancers (Basel) 2020;12:E3811. [PMID: 33348689 DOI: 10.3390/cancers12123811] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
5 Filippi S, Paccosi E, Balzerano A, Ferretti M, Poli G, Taborri J, Brancorsini S, Proietti-de-santis L. CSA Antisense Targeting Enhances Anticancer Drug Sensitivity in Breast Cancer Cells, including the Triple-Negative Subtype. Cancers 2022;14:1687. [DOI: 10.3390/cancers14071687] [Reference Citation Analysis]
6 Jiang X, Guo S, Xu M, Ma B, Liu R, Xu Y, Zhang Y. TFAP2C-Mediated lncRNA PCAT1 Inhibits Ferroptosis in Docetaxel-Resistant Prostate Cancer Through c-Myc/miR-25-3p/SLC7A11 Signaling. Front Oncol 2022;12:862015. [DOI: 10.3389/fonc.2022.862015] [Reference Citation Analysis]
7 Ren Y, Wang Y, Li G, Zhang Z, Ma L, Cheng B, Chen J. Discovery of Novel Benzimidazole and Indazole Analogues as Tubulin Polymerization Inhibitors with Potent Anticancer Activities. J Med Chem 2021;64:4498-515. [PMID: 33788562 DOI: 10.1021/acs.jmedchem.0c01837] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
8 Huang P, Li F, Mo Z, Geng C, Wen F, Zhang C, Guo J, Wu S, Li L, Brünner N, Stenvang J. A Comprehensive RNA Study to Identify circRNA and miRNA Biomarkers for Docetaxel Resistance in Breast Cancer. Front Oncol 2021;11:669270. [PMID: 34055636 DOI: 10.3389/fonc.2021.669270] [Reference Citation Analysis]
9 Tőkés AM, Vári-kakas S, Kulka J, Törőcsik B. Tumor Glucose and Fatty Acid Metabolism in the Context of Anthracycline and Taxane-Based (Neo)Adjuvant Chemotherapy in Breast Carcinomas. Front Oncol 2022;12:850401. [DOI: 10.3389/fonc.2022.850401] [Reference Citation Analysis]
10 Yu DL, Lou ZP, Ma FY, Najafi M. The interactions of paclitaxel with tumour microenvironment. Int Immunopharmacol 2022;105:108555. [PMID: 35121223 DOI: 10.1016/j.intimp.2022.108555] [Reference Citation Analysis]
11 Sasitharan K, Iqbal HA, Bifsa F, Olszewska A, Linton KJ. ABCB1 Does Not Require the Side-Chain Hydrogen-Bond Donors Gln347, Gln725, Gln990 to Confer Cellular Resistance to the Anticancer Drug Taxol. Int J Mol Sci 2021;22:8561. [PMID: 34445264 DOI: 10.3390/ijms22168561] [Reference Citation Analysis]
12 Español A, Salem A, Sanchez Y, Sales ME. Breast cancer: Muscarinic receptors as new targets for tumor therapy. World J Clin Oncol 2021; 12(6): 404-428 [PMID: 34189066 DOI: 10.5306/wjco.v12.i6.404] [Reference Citation Analysis]
13 Mirzaei S, Zarrabi A, Asnaf SE, Hashemi F, Zabolian A, Hushmandi K, Raei M, Goharrizi MASB, Makvandi P, Samarghandian S, Najafi M, Ashrafizadeh M, Aref AR, Hamblin MR. The role of microRNA-338-3p in cancer: growth, invasion, chemoresistance, and mediators. Life Sci 2021;268:119005. [PMID: 33421526 DOI: 10.1016/j.lfs.2020.119005] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
14 Madamsetty VS, Tavakol S, Moghassemi S, Dadashzadeh A, Schneible JD, Fatemi I, Shirvani A, Zarrabi A, Azedi F, Dehshahri A, Aghaei Afshar A, Aghaabbasi K, Pardakhty A, Mohammadinejad R, Kesharwani P. Chitosan: A versatile bio-platform for breast cancer theranostics. J Control Release 2021;341:733-52. [PMID: 34906606 DOI: 10.1016/j.jconrel.2021.12.012] [Reference Citation Analysis]
15 Lukanović D, Kobal B, Černe K. Ovarian Cancer: Treatment and Resistance to Pharmacotherapy. Reprod Med 2022;3:127-40. [DOI: 10.3390/reprodmed3020011] [Reference Citation Analysis]
16 Mohammadinejad R, Madamsetty VS, Kumar A, Varzandeh M, Dehshahri A, Zarrabi A, Sharififar F, Mohammadi M, Fahimipour A, Ramakrishna S. Electrospun nanocarriers for delivering natural products for cancer therapy. Trends in Food Science & Technology 2021;118:887-904. [DOI: 10.1016/j.tifs.2021.10.007] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
17 Mahmoud N, Dawood M, Huang Q, Ng JPL, Ren F, Wong VKW, Efferth T. Nimbolide inhibits 2D and 3D prostate cancer cells migration, affects microtubules and angiogenesis and suppresses B-RAF/p.ERK-mediated in vivo tumor growth. Phytomedicine 2022;94:153826. [PMID: 34775358 DOI: 10.1016/j.phymed.2021.153826] [Reference Citation Analysis]
18 Ruiz de Porras V, Font A, Aytes A. Chemotherapy in metastatic castration-resistant prostate cancer: Current scenario and future perspectives. Cancer Lett 2021;523:162-9. [PMID: 34517086 DOI: 10.1016/j.canlet.2021.08.033] [Reference Citation Analysis]
19 Currie J, Demeule M, Charfi C, Zgheib A, Larocque A, Danalache BA, Ouanouki A, Béliveau R, Marsolais C, Annabi B. The Peptide-Drug Conjugate TH1902: A New Sortilin Receptor-Mediated Cancer Therapeutic against Ovarian and Endometrial Cancers. Cancers 2022;14:1877. [DOI: 10.3390/cancers14081877] [Reference Citation Analysis]